Physician profile
James L Krantz
NPI 1801992029
$22,743.98
in general payments reported to CMS, 2019-2025
62 companies · $1,204 in 2025
The $1,204 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,455 · 2020: $5,338 · 2021: $6,358 · 2022: $2,509 · 2023: $2,505 · 2024: $2,376 · 2025: $1,204.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,985 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,985.05 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,300.05 | 2019-2025 | |
| Allergan, INC. | $3,098.05 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $2,857.20 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $1,596.29 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Novo Nordisk INC | $1,385.70 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,179.54 | 2019-2025 | Jardiance, Stiolto Respimat, Synjardy |
| Pfizer INC. | $871.96 | 2019-2025 | |
| Glaxosmithkline, LLC. | $693.39 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $661.12 | 2019-2025 | Repatha, Otezla, Evenity |
| Astellas Pharma US INC | $580.53 | 2019-2024 | Veozah |
| Sanofi-Aventis U.S. LLC | $417.58 | 2019-2023 | |
| Medtronic, INC. | $397.99 | 2022-2024 | Intellis Adaptivestim, Vanta Adaptivestim, Minimed 780g |
| Janssen Pharmaceuticals, INC | $363.87 | 2019-2023 | Xarelto |
| Merck Sharp & Dohme LLC | $355.29 | 2019-2024 | Verquvo, Belsomra, Steglatro |
| Takeda Pharmaceuticals U.S.A., INC. | $283.18 | 2019-2025 | Trintellix |
Show all 62 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Krantz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.